Is APT a good stock to buy right now?

Based on our 6-factor quantitative model, ALPHA PRO TECH LTD (APT) receives a "Hold" rating with a composite score of 51.3/100. It is ranked #1,650 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 69/100, Momentum 40/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for APT?

ALPHA PRO TECH LTD (APT) has a "Hold" rating and 3-star score. The composite score of 51.3 ranks it #1,650 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is APT in?

ALPHA PRO TECH LTD operates in the Healthcare sector (Medical Equipment industry) with a market cap of $48 million. It is classified as a micro-cap stock.

Does APT pay a dividend?

APT does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is APT's P/E ratio?

APT has a trailing P/E ratio of 12.57x. The Healthcare sector average is 23.6x. This below-average P/E may indicate the stock is undervalued.

How profitable is APT?

APT's quality factor score is 50/100. Gross margin: 38.5%. ROE: 5.9% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is APT valued compared to peers?

APT's value factor score is 69/100 (higher = cheaper). Key multiples: P/E 12.6x, EV/EBITDA 12.8x. The stock appears attractively valued versus peers.

What is APT's debt level?

APT's debt-to-equity ratio is 19%. Sector average: 32%. Low leverage suggests conservative financial management.

APT has a beta of 0.38, meaning it is less volatile than the market. Stability score: 74/100.

Does APT have high short interest?

APT's short interest factor score is 48/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

APT Stock Analysis: Top Micro-Cap Hold (Score 51.3/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
APT	-2.38%	+1.58%	-12.60%	+1.58%	+8.15%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-2.31%	-2.03%	-12.93%	+1.94%	-21.37%	-	-	-
Alpha vs Sector	-1.03%	+1.24%	-8.78%	+6.42%	-1.05%	-	-	-

Metric	APT	Benchmark
P/E Ratio	12.6x	-47%
EV/EBITDA	12.8x	+102%
Price / Book	0.7x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
APT ALPHA PRO TECH LTD	51	50	69	40	12.6x	5.9%	38.5%	6.1%	-9.2%	19.0x	$48M
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.4%	0.4%	0.4%	0.4%	0.3%	0.4%	0.5%	0.4%	0.4%	0.4%	0.4%
Operating Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.3%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.3%	0.1%	0.1%	0.1%	0.1%
Net Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.3%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	2.8%	-	-	-	-	-	16.7%	3.9%	3.0%	6.3%	14.2%
ROE %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.5%	0.1%	0.1%	0.1%	0.1%
ROA %	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.4%	0.1%	0.1%	0.1%	0.1%
ROIC %	6.4%	4.9%	4.4%	5.3%	6.0%	10.0%	68.8%	8.9%	12.2%	10.2%	12.5%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.4%

0.3%

0.4%

0.5%

0.4%

Operating Margin %

0.1%

0.3%

0.1%

EBITDA Margin %

0.1%

0.3%

0.1%

Net Margin %

0.1%

0.3%

0.1%

FCF Margin %

2.8%

16.7%

3.9%

3.0%

6.3%

14.2%

ROE %

0.1%

0.5%

0.1%

ROA %

0.0%

0.1%

0.4%

0.1%

ROIC %

6.4%

4.9%

4.4%

5.3%

6.0%

10.0%

68.8%

8.9%

12.2%

10.2%

12.5%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$60M	$59M	$58M	$61M	$62M	$69M	$103M	$47M	$47M	$44M	$46M	$45M
	—	$37M	$35M	$38M	$40M	$43M	—	—	—	—	—	—
	$23M	$23M	$23M	$23M	$22M	$25M	$50M	$17M	$18M	$17M	$17M	$16M
Gross Margin	38.5%	38.1%	39.6%	37.3%	35.0%	36.9%	49.1%	36.4%	38.0%	39.6%	36.8%	35.5%
	—	$18M	$19M	$18M	$16M	$17M	—	—	—	—	—	—
Depreciation	—	$925K	$873K	$925K	$814K	$813K	$729K	$602K	$525K	$571K	$544K	$703K
Total Operating Expenses	—	$19M	$19M	$19M	$17M	$17M	—	—	—	—	—	—
	$4M	$4M	$3M	$4M	$5M	$8M	$32M	$3M	$4M	$3M	$4M	$1M
EBIT	$5M	$4M	$3M	$4M	$5M	$8M	$32M	$3M	$4M	$3M	$4M	$1M
EBITDA	$4M	$5M	$4M	$5M	$5M	$9M	$32M	$4M	$4M	$4M	$4M	$2M
Operating Margin	6.0%	6.5%	6.0%	6.8%	7.5%	11.6%	30.8%	6.5%	8.3%	6.7%	8.0%	3.3%
EBITDA Margin	6.1%	8.1%	7.5%	8.3%	8.8%	12.7%	31.4%	8.3%	9.3%	8.8%	9.1%	4.8%
	—	$59M	$58M	$61M	$62M	$69M	—	—	—	—	—	—
Income Tax Expense	—	$1M	$1M	$1M	$1M	$2M	$5M	$680K	$789K	$1M	$1M	$480K
	$4M	$4M	$4M	$4M	$3M	$7M	$27M	$3M	$4M	$3M	$3M	$1M
Net Margin	6.1%	6.0%	6.8%	6.8%	5.3%	9.8%	26.2%	6.4%	7.8%	6.0%	6.9%	2.3%
	$0.34	$0.34	$0.35	$0.35	$0.26	$0.51	$2.01	$0.23	$0.26	$0.18	$0.19	$0.06
Diluted EPS	$0.34	$0.33	$0.35	$0.35	$0.26	$0.50	$2.01	$0.23	$0.26	$0.18	$0.19	$0.06
Weighted Avg Basic	—	10M	11M	12M	13M	13M	—	—	—	—	—	—
Weighted Avg Diluted	—	11M	11M	12M	13M	13M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$60M

$59M

$58M

$61M

$62M

$69M

$103M

$47M

$44M

$46M

$45M

—

$37M

$35M

$38M

$40M

$43M

—

$23M

$22M

$25M

$50M

$17M

$18M

$17M

$16M

Gross Margin

38.5%

38.1%

39.6%

37.3%

35.0%

36.9%

49.1%

36.4%

38.0%

39.6%

36.8%

35.5%

—

$18M

$19M

$18M

$16M

$17M

—

Depreciation

—

$925K

$873K

$925K

$814K

$813K

$729K

$602K

$525K

$571K

$544K

$703K

Total Operating Expenses

—

$19M

$17M

—

$4M

$3M

$4M

$5M

$8M

$32M

$3M

$4M

$3M

$4M

$1M

EBIT

$5M

$4M

$3M

$4M

$5M

$8M

$32M

$3M

$4M

$3M

$4M

$1M

EBITDA

$4M

$5M

$4M

$5M

$9M

$32M

$4M

$2M

Operating Margin

6.0%

6.5%

6.0%

6.8%

7.5%

11.6%

30.8%

6.5%

8.3%

6.7%

8.0%

3.3%

EBITDA Margin

6.1%

8.1%

7.5%

8.3%

8.8%

12.7%

31.4%

8.3%

9.3%

8.8%

9.1%

4.8%

—

$59M

$58M

$61M

$62M

$69M

—

Income Tax Expense

—

$1M

$2M

$5M

$680K

$789K

$1M

$480K

$4M

$3M

$7M

$27M

$3M

$4M

$3M

$1M

Net Margin

6.1%

6.0%

6.8%

5.3%

9.8%

26.2%

6.4%

7.8%

6.0%

6.9%

2.3%

$0.34

$0.35

$0.26

$0.51

$2.01

$0.23

$0.26

$0.18

$0.19

$0.06

Diluted EPS

$0.34

$0.33

$0.35

$0.26

$0.50

$2.01

$0.23

$0.26

$0.18

$0.19

$0.06

Weighted Avg Basic

—

10M

11M

12M

13M

—

Weighted Avg Diluted

—

11M

12M

13M

—

ALPHA PRO TECH LTD (APT) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does ALPHA PRO TECH LTD Do?

Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through two segments, Disposable Protective Apparel and Building Supply. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, and synthetic roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada. ALPHA PRO TECH LTD (APT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Lloyd Hoffman and employs approximately 120 people, headquartered in MARKHAM ONTARIO CANA, Ontario. With a market capitalization of $48M, APT is one of the notable companies in the Healthcare sector.

ALPHA PRO TECH LTD (APT) Stock Rating — Hold (April 2026)

As of April 2026, ALPHA PRO TECH LTD receives a Hold rating with a composite score of 51.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.APT ranks #1,650 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ALPHA PRO TECH LTD ranks #151 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

APT Stock Price and 52-Week Range

ALPHA PRO TECH LTD (APT) currently trades at $4.51. The stock lost $0.11 (2.4%) in the most recent trading session. The 52-week high for APT is $5.64, which means the stock is currently trading -20.0% from its annual peak. The 52-week low is $4.06, putting the stock 11.1% above its annual trough. Recent trading volume was 29K shares, suggesting relatively thin trading activity.

Is APT Overvalued or Undervalued? — Valuation Analysis

ALPHA PRO TECH LTD (APT) carries a value factor score of 69/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 12.57x, compared to the Healthcare sector average of 23.63x — a discount of 47%. The price-to-book ratio stands at 0.74x, versus the sector average of 2.75x. The price-to-sales ratio is 0.78x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, APT trades at 12.82x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 8.56x.

Overall, APT's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

ALPHA PRO TECH LTD Profitability — ROE, Margins, and Quality Score

ALPHA PRO TECH LTD (APT) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 5.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 5.0% versus the sector average of -33.1%.

On a margin basis, ALPHA PRO TECH LTD reports gross margins of 38.5%, compared to 71.5% for the sector. The operating margin is 6.0% (sector: -66.1%). Net profit margin stands at 6.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -9.2% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

APT Debt, Balance Sheet, and Financial Health

ALPHA PRO TECH LTD has a debt-to-equity ratio of 19.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.94x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $18M.

APT has a beta of 0.38, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ALPHA PRO TECH LTD is 74/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

ALPHA PRO TECH LTD Revenue and Earnings History — Quarterly Trend

In TTM 2026, ALPHA PRO TECH LTD reported revenue of $60M and earnings per share (EPS) of $0.34. Net income for the quarter was $4M. Gross margin was 38.5%. Operating income came in at $4M.

In FY 2025, ALPHA PRO TECH LTD reported revenue of $59M and earnings per share (EPS) of $0.34. Net income for the quarter was $4M. Gross margin was 38.1%. Revenue grew 2.3% year-over-year compared to FY 2024. Operating income came in at $4M.

In Q3 2025, ALPHA PRO TECH LTD reported revenue of $15M and earnings per share (EPS) of $0.09. Net income for the quarter was $976,000. Gross margin was 39.7%. Revenue grew 3.7% year-over-year compared to Q3 2024. Operating income came in at $1M.

In Q2 2025, ALPHA PRO TECH LTD reported revenue of $17M and earnings per share (EPS) of $0.12. Net income for the quarter was $1M. Gross margin was 36.8%. Revenue grew 2.4% year-over-year compared to Q2 2024. Operating income came in at $1M.

Over the past 8 quarters, ALPHA PRO TECH LTD has demonstrated a growth trajectory, with revenue expanding from $16M to $60M. Investors analyzing APT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

APT Dividend Yield and Income Analysis

ALPHA PRO TECH LTD (APT) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

APT Momentum and Technical Analysis Profile

ALPHA PRO TECH LTD (APT) has a momentum factor score of 40/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 36/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

APT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ALPHA PRO TECH LTD (APT) ranks #151 out of 838 stocks based on the Blank Capital composite score. This places APT in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing APT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full APT vs S&P 500 (SPY) comparison to assess how ALPHA PRO TECH LTD stacks up against the broader market across all factor dimensions.

APT Next Earnings Date

No upcoming earnings date has been announced for ALPHA PRO TECH LTD (APT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy APT? — Investment Thesis Summary

ALPHA PRO TECH LTD presents a balanced picture with arguments on both sides. The value score of 69/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 74/100) reduces downside risk.

In summary, ALPHA PRO TECH LTD (APT) earns a Hold rating with a composite score of 51.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on APT stock.

Related Resources for APT Investors

Explore more research and tools: APT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare APT head-to-head with peers: APT vs AZN, APT vs SLGL, APT vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Alpha Pro Tech, Ltd. Announces Fourth Quarter and Full Year 2025 Financial Results

Despite Plenty of Positive News, Aptos Sinks Another 5% Today

Alpha Pro Tech, Ltd. Announces Third Quarter 2025 Financial Results

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

ALPHA PRO TECH LTD (APT) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does ALPHA PRO TECH LTD Do?

ALPHA PRO TECH LTD (APT) Stock Rating — Hold (April 2026)

APT Stock Price and 52-Week Range

Is APT Overvalued or Undervalued? — Valuation Analysis

ALPHA PRO TECH LTD Profitability — ROE, Margins, and Quality Score

APT Debt, Balance Sheet, and Financial Health

ALPHA PRO TECH LTD Revenue and Earnings History — Quarterly Trend

APT Dividend Yield and Income Analysis

APT Momentum and Technical Analysis Profile

APT vs Competitors — Healthcare Sector Ranking and Peer Comparison

APT Next Earnings Date

Should You Buy APT? — Investment Thesis Summary

Related Resources for APT Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Alpha Pro Tech, Ltd. Announces Fourth Quarter and Full Year 2025 Financial Results

Despite Plenty of Positive News, Aptos Sinks Another 5% Today

Alpha Pro Tech, Ltd. Announces Third Quarter 2025 Financial Results